European Healthtech Grabs The Investor Headlines In H1 2022
Cautious Optimism For Sector And M&A Set To Stay Strong In 2022
After a runaway 2021 and a strong if bumpy Q1 2022, all health care product sectors underwent an investment dip in Q2, says Silicon Valley Bank. Healthtech in Europe remained a stand-out performer.
You may also be interested in...
The pressures on global medtechs to focus more on sustainability are internal as well as external. Scope 3 adds yet another layer of compliance. Johnson & Johnson’s EMEA VP for Surgical Vision Erin McEachren explains to In Vivo how her organization meets these challenges while simultaneously addressing EU Medical Device Regulation requirements and ensuring patient safety standards.
As the health care sector moves from linear to circular, medtechs, providers and patients all have roles to play in ensuring that current strategies, practices and behaviors contribute to guarantee a sustainable future. Part one of a short series on this theme looks as best practice for providers.
Outside the EU and no longer enjoying an MRA with the bloc, Switzerland has had to develop its own medical device database, work on which will continue into next year.